Foghorn Therapeutics (FHTX) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 15.8% versus a loss of 55.8%. Over five years, FHTX leads with a -83.9% price change compared with -91.3% for IMUX. Foghorn Therapeutics is the larger company by market cap ($121.4 million vs $112.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | IMUX |
|---|---|---|
| Share price | $2.05 | $8.23 |
| Market cap | $121.44M | $112.29M |
| 1-day change | +2.76% | +8.86% |
| YTD return | -63.15% | +41.57% |
| 1-year return | -55.78% | -15.81% |
| 5-year return | -83.93% | -91.28% |
| EPS (TTM) | $-0.98 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $17.43 |
| 52-week low | $1.79 | $5.06 |
| Distance from 52-week high | -73.13% | -52.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +193.40% | +423.57% |
| Average volume | 629.61K | 284.68K |
| Shares outstanding | 59.39M | 13.64M |
| Employees | 106 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed FHTX by 40.0 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
FHTX vs IMUX FAQ
Which is bigger, Foghorn Therapeutics or Immunic?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $121.44M compared with $112.29M for Immunic (IMUX).
Which stock has performed better over the past year, FHTX or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -55.78% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.